Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 6065-6073

  Matsui, Shigeyuki ^a   Simon, Richard ^b   Qu, Pingping ^c   Shaughnessy, John D ^d   Barlogie, Bart ^d   Crowley, John ^c  

^a INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; THALIDOMIDE;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 84868574658     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1206     Document Type: Article

References (24)

1. Balis FM. Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst 2002;94:78-9. (Pubitemid 34121279)
2. Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002;8:935-8. (Pubitemid 35177337)
3. Rothenberg ML, Carbone DP, Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 2003;3:303-9. (Pubitemid 37328866)
4. Hoering A, Leblanc M, Crowley JJ. Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res 2008;14:4358-67.
5. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8. (Pubitemid 41611633)
6. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010;16:691-8.
7. Janes H, Pepe MS, Bossuyt PM, Barlow WE. Measuring the performance of markers for guiding treatment decisions. Ann Intern Med 2011;154:253-9.
8. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30. (Pubitemid 43357806)
9. Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD Jr, Szymonifka J, Hoering A, et al. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol 2010;28:3023-7.
10. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A 2002;99:6562-6. (Pubitemid 34526172)
11. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-8. (Pubitemid 36124291)
12. Dudoit S, Fridlyand J. Classification in microarray experiments. In: Speed TP, editor. Statistical analysis of gene expression microarray data. Boca Raton, FL: Chapman & Hall/CRC; 2003. p. 93-158.
13. Varma S, Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics 2006;7:91.
14. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling (with discussion). Appl Stat 1994;43:429-67.
15. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al.The use ofmolecular profilingto predict survivalafterchemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47. (Pubitemid 34651353)
16. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
17. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-84. (Pubitemid 46425864)
18. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9. (Pubitemid 44200649)
19. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
20. Simon RM, Korn EL, McShane LM, Radmacher MD, Wright GW, Zhao Y. Design and analysis of DNA microarray investigations. New York: Springer; 2004.
21. Tukey JW. Tightening the clinical trial. Control Clin Trials 1993;14:266-85. (Pubitemid 23256746)
22. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002;9:505-911.
23. Matsui S. Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays. BMC Bioinformatics 2006;7:156.
24. Witten DM, Tibshirani R. Survival analysis with high-dimensional covariates. Stat Methods Med Res 2010;19:29-51.